Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies

Antiviral Therapy

Volumn 19, Issue 8, 2014, Pages 799-803

  Labarga, Pablo ^a   Fernández Montero, Jose V ^a   López, Mariola ^a   Barreiro, Pablo ^a   De Mendoza, Carmen ^a,b   Sierra Enguita, Rocío ^a   Treviño, Ana ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; ELASTOGRAPH; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MIXED INFECTION; NONHUMAN; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ADULT; COMPLICATION; ELASTOGRAPHY; FEMALE; FOLLOW UP; GENETICS; GENOTYPE; HEPACIVIRUS; HIV INFECTIONS; IMMUNOLOGY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; COINFECTION; DISEASE PROGRESSION; ELASTICITY IMAGING TECHNIQUES; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84922449305     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2816     Document Type: Article

References (28)

1. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014; 61:373-395.
2. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double blind, controlled Phase 2 trial. Lancet Infect Dis 2013; 13:597-605.
3. Sulkowski M, Sherman K, Dieterich D, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159:86-96.
4. Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC). J Hepatol 2013; 59:434-441.
5. Cachay E, Wyles D, Torriani F, et al. High incidence of serious adverse events in HIV-infected patients treated with a telaprevir based HCV treatment regimen. AIDS 2013; 27:2893-2897.
6. Fried MW, Buti M, Dore G, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C - the randomized PILLAR study. Hepatology 2013; 58:1918-1929.
7. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases the rate of sustained virological response among treatment-experienced patients with HCV genotype 1 infection - a Phase IIb trial. Gastroenterology 2014; 146:430-441.
8. Sulkowski MS, Asselah T, Lalezari J, et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology 2013; 57:2143-2154.
9. Sulkowski M, Bourliere M, Bronowicki JP, et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype 1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 2013; 57:2155-2163.
10. Soriano V, Vispo E, de Mendoza C, et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother 2013; 14:1161-1170.
11. Medrano J, Neukam K, Rallon N, et al. Modeling the probability of SVR to therapy with pegylated interferon plus ribavirin in patients coinfected with HCV and HIV. Clin Infect Dis 2010; 51:1209-1216.
12. European AIDS Clinical Society Guidelines (EACS). Version 7.0. October 2013. (Accessed 31 January 2014.) Available from http://www.europeanaidsclinicalsociety.org
13. Bichoupan K, Schwartz JM, Martel-Laferriere V, et al. Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther 2014; 39:209-216.
14. Shiffman ML, Benhamou Y. Patients with HCV and F1 and F2 fibrosis stage: treat now or wait? Liver Int 2013; 33 Suppl 1:105-110.
15. EASL. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014; 61:373-395.
16. Soriano V, Vispo E, Fernandez-Montero JV, Labarga P, Barreiro P. Update on HIV/HCV coinfection. Curr HIV/AIDS Rep 2013; 10:226-234.
17. Thompson MA, Aberg J, Hoy J, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
18. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Accessed 31 January 2014.) Available from http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf
19. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48:835-847.
20. Sulkowski MS, Mehta S, Torbenson M, et al. Rapid fibrosis progression among HIV/HCV coinfected adults. AIDS 2007; 21:2209-2216.
21. Macías J, Berenguer J, Japón M, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with HIV and HCV. Hepatology 2009; 50:1056-1063.
22. Fernández-Montero JV, Barreiro P, Vispo E, et al. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon-ribavirin therapy. Antivir Ther 2014; 19:287-292.
23. Sanmartín R, Tor J, Sanvisens A, et al. Progression of liver fibrosis in HIV/HCV-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline. HIV Med 2014; 15:203-212.
24. Soriano V, Labarga P, Fernández-Montero JV, et al. The changing face of hepatitis C in the new era of direct-acting antivirals. Antiviral Res 2013; 97:36-40.
25. Younossi ZM, Singer M, Mir H, Henry L, Hunt S. Impact of interferon-free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014; 60:530-537.
26. Barreiro P, Labarga P, Martín-Carbonero L, et al. Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients. Antivir Ther 2006; 11:869-877.
27. Loko MA, Bani-Sadr F, Valantin MA, et al . Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort. Antivir Ther 2012; 17:1335-1343.
28. Konerman MA, Mehta S, Sutcliffe C, et al. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: Prospective analysis of 435 liver biopsy pairs. Hepatology 2014; 59:767-775.